1 / 12

Patterns of Care in Medical Oncology

Patterns of Care in Medical Oncology. Neoadjuvant and Adjuvant Treatment of Rectal Cancer. To approximately how many patients with rectal cancer have you administered neoadjuvant chemoradiation therapy in the past year?.

malini
Download Presentation

Patterns of Care in Medical Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer

  2. To approximately how many patients with rectal cancer have you administered neoadjuvant chemoradiation therapy in the past year?

  3. Preoperative radiation therapy combined with capecitabine and oxaliplatin versus radiation therapy combined with 5-FU and oxaliplatin for patients with resectable rectal cancer Protocol ID: NSABP-R-04, Target Accrual: 1,606 (Open) 5-FU + radiation therapy Continuous infusion 5-FU 225 mg/m2 per day for 5 days per week on days of planned radiation therapy (RT*) R 5-FU + radiation therapy + oxaliplatin Same as arm 1, with oxaliplatin 50 mg/m2 weekly x 5 during RT* *4,500 cGy in 25 fractions over five weeks with a 540-cGy boost in three fractions for nonfixed tumors or a 1,080-cGy boost in six fractions for fixed tumors Source: NSABP-R-04 Protocol, November 24, 2008.

  4. Preoperative radiation therapy combined with capecitabine and oxaliplatin versus radiation therapy combined with 5-FU and oxaliplatin for patients with resectable rectal cancer Protocol ID: NSABP-R-04, Target Accrual: 1,606 (Open) Capecitabine + radiation therapy Capecitabine 825 mg/m2 BID 5 days per week on days of planned RT* R Capecitabine + radiation therapy + oxaliplatin Same as arm 3, with oxaliplatin 50 mg/m2 weekly x 5 during RT* *4,500 cGy in 25 fractions over five weeks with a 540-cGy boost in three fractions for nonfixed tumors or a 1,080-cGy boost in six fractions for fixed tumors Source: NSABP-R-04 Protocol, November 24, 2008.

  5. When administering a fluoropyrimidine during radiation therapy, which regimen do you generally recommend?

  6. Patients who receive 5-FU/LV with radiation therapy for neoadjuvant treatment of rectal cancer and have positive nodes in the resection specimen postoperatively should generally receive which of the following regimens?

  7. Have you used oxaliplatin off protocol as part of neoadjuvant chemoradiation therapy for rectal cancer? CI n = 12; PO n = 22

  8. Have you used bevacizumab off protocol as part of neoadjuvant chemoradiation therapy for rectal cancer? CI n = 0; PO n = 7

  9. For the patient with rectal cancer at the anal verge who achieves a clinical complete response with a negative biopsy of the primary site after neoadjuvant chemoradiation therapy, surveillance with delayed resection at recurrence is acceptable.

  10. Case 6: Rectal Cancer • A 65-year-old man in average health • T3N0 rectal cancer by endoscopic ultrasound • Lesion is 8 centimeters from the anal verge

  11. Case 7: Rectal Cancer • A 65-year-old man in average health • T3N1 rectal cancer (2 enlarged lymph nodes on endoscopic ultrasound) • Lesion is 8 centimeters from the anal verge

  12. Case 8: Rectal Cancer After Neoadjuvant Treatment and with Complete Pathologic Response Evident on Resection, Including Absence of Residual Nodal Disease • Man in average health • T3N1 rectal cancer (2 enlarged lymph nodes on endoscopic ultrasound) • Lesion is 8 centimeters from the anal verge • Undergoes neoadjuvant chemoradiation therapy with XELOX/CAPOX • Complete pathologic response evident on resection

More Related